Navigation Links
MedQuist Reports First Quarter 2008 Results
Date:5/12/2008

rtain injunctive relief. The court has been notified of the tentative settlement and the lawsuit has been stayed while the parties continue to negotiate the settlement documentation. The tentative settlement contemplates notice to a settlement class consisting of all medical transcriptionists paid by the line for the period from November 29, 1998 through execution of the settlement agreement and is conditioned on final approval by the court.

Forward-Looking Statements

This report contains forward-looking statement that are based on current expectations, estimates, forecasts and projections about us, the industry in which we operate and other matters, as well as management's beliefs and assumptions and other statements regarding matters that are not historical facts. These statements include, in particular, statements about our plans, strategies and prospects. For example, when we use words such as "projects," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "should," "would," "could," "will," "opportunity," "potential" or "may," variations of such words or other words that convey uncertainty of future events or outcomes, we are making forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (Securities Act) and Section 21E of the Exchange Act. These statements are only predictions and, as such, are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict, including, without limitation, the risk that a settlement is not ever reached in the consolidated medical transcriptionists' putative class action lawsuit. For a discussion of these risks, uncertainties and assumptions, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the section of MedQuist's Annual Report on Form 10-K for the year ended December 31, 2007, entitled "Risk Factors" and discussions of potential risks a
'/>"/>

SOURCE MedQuist Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. QLT reports initial proof of concept data for punctal plug delivery technology
2. Neurobiological Technologies Reports Third Quarter Financial Results
3. Bionovo Reports First Quarter 2008 Financial Results
4. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
5. Cardium Reports on First Quarter 2008 Highlights and Financial Results
6. Novavax Reports First Quarter 2008 Financial Results
7. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
8. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
9. Pharmos Corporation Reports 2008 First Quarter Results
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic ... expanded its myPROpad™ ePRO tablet with the addition of ... the most widely used and well-respected Patient Reported Outcome ... EQ-5D is used during clinical trials and in other ... be used to demonstrate Health-Related Quality of Life outcomes ...
(Date:8/19/2014)... Shimadzu Scientific Instruments has introduced ... Nexera-i, adding to the company’s extensive line-up of ... intuitive operating environment, and full automation, the i-Series ... for conventional to ultra-high-speed analysis. , ... design so users can begin building the lab ...
(Date:8/19/2014)... IRVINE, Calif. (PRWEB) August 19, 2014 ... Indiegogo campaign to raise $200,000 to fund a ... diagnostic device. , This development is a ... one-size-fits-all model of care to the implementation of ... patient-centric method of practicing medicine. , Indiegogo contributions ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership ... production from bioactive small molecules. Based on ... enables convenient and timely assessment of critical metabolite ... President of Commercial Operations, Christian Darabant, “the value ... can be measured directly by comparison with the ...
Breaking Biology Technology:EQ-5D™ Assessment Now Available for iPad 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... Inc. (NASDAQ: AUXL ), a specialty biopharmaceutical ... of post-approval use in the U.S. of XIAFLEX® for ... palpable cord.  After approximately 11,000 injections administered to approximately ... meaningful change in the nature of events expected relative ...
... 2011 Genprex, Inc., formerly known as Convergen ... nanomolecular cancer therapy CNVN202, will be branded as Oncoprex™ ... brand in the oncology sector in recognition of our ... will be used to unlock the unrealized potential of ...
... - QIAGEN assay for JAK2 V617F mutation ... ,JAK2 inhibitor, and to monitor responses to therapy ... exclusive access to JAK2 biomarker underpins potential future expansion with ... QGEN ; Frankfurt, Prime Standard: QIA) today announced that ...
Cached Biology Technology:Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 2Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 3Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 4Genprex Announces New Branding 2QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 2QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 3QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 4
(Date:8/19/2014)... at San Antonio and The University of Texas at ... than $750,000 in grants through the San Antonio Life ... SALSI is a model of how a general academic ... forces for greater research and graduate education. , The ... public health issues and diseases of global impact. Funding ...
(Date:8/19/2014)... August 2014: An engineer at the University of Liverpool ... a brain to communicate with the body. , Dr ... Mahadevan, has developed a mathematical model for earthworms and ... these soft bodied animals get around. , The most ... generator (CPG) which states that the central brain of ...
(Date:8/19/2014)... study that analyzed concentrations of African dust transported ... winter and spring. These research findings offer new ... quality impacts of African dust, including the climate ... occur from increased African dust emissions in the ... (UM) Rosenstiel School of Marine and Atmospheric Science ...
Breaking Biology News(10 mins):San Antonio Life Sciences Institute awards $750,000 to innovators 2San Antonio Life Sciences Institute awards $750,000 to innovators 3Secrets of how worms wriggle uncovered 2Study of African dust transport to South America reveals air quality impacts 2
... , The University of Haifa, Israel, has dedicated Israel,s ... focus on research and development of non-irrigated green roofs; ... and evolutionary theories. The center has been ... expert in the field, and was facilitated by VP ...
... Investigators at Washington University and The Scripps Research Institute ... to facilitate meta-analyses on studies of the metabolism of ... of the Global Metabolomic Initiative was sent to more ... a total of more than 35,000 files of metabolomic ...
... und MÜNCHEN, 7. November 2012 Bausch + Lomb, ... er seine Option zum Kauf aller im Umlauf befindlichen ... GmbH (TPV) ausgeübt hat, einem führenden Hersteller ophthalmologischer Lasersysteme. ... aus einem Joint Venture zwischen Bausch + Lomb und ...
Cached Biology News:Israel's first Green Roofs Ecology research center dedicated at University of Haifa 2Global metabolomic initiative announced 2Global metabolomic initiative announced 3Global metabolomic initiative announced 4Bausch + Lomb übernimmt Technolas Perfect Vision GmbH 2Bausch + Lomb übernimmt Technolas Perfect Vision GmbH 3Bausch + Lomb übernimmt Technolas Perfect Vision GmbH 4
... compatible with hood installations. ... system for 384-well plates, ... prepares large quantities of ... Wellpro also performs plate ...
MBS 384 well satellite block unit with height adjusting heated lid, 384 well block holds 1 x 0.04 ml 384 well plate...
... structure has been determined, the challenge is ... diverse audience of scientists, educators and students. ... dissemination over the Internet, either via online ... Printed literature has the advantage of wide ...
... 45° Fixed Angle rotor for ... CL2, Centra CL3/CL3R, HN-SII or ... style rotor accepts 15 mL ... disposable conical tubes as well ...
Biology Products: